Championing Health for All
- Health at Bayer
Treatments & Therapies
- Chronic Kidney Disease
- Eye Conditions
- Healthy Aging
- Hormonal & Reproductive Health
Innovation & Technologies
- Patient Access Charter
- Leadership Perspective
- Strengthening Healthcare Access
- Empowering Women, Globally
- Fighting Neglected Tropical Diseases
- Moving Non-Communicable Diseases Care Forward
- Ensuring a Sustainable Product Supply
- Delivering Better Cancer Care
- News & Stories
- Clinical Trials Explorer
- Treatments & Therapies
- Our Commitments
- Report a Side Effect
- Medical Counterfeits
We are committed to helping shape a world where everyone can access the resources and care they need to lead a healthy life – that’s why 'Health for All, Hunger for None' is our vision at Bayer.
Access to quality healthcare and gender equality are key indicators for social and economic prosperity. The World Health Organization has reported that at least half of the world’s population lacks access to essential health services, with 100 million people still pushed into extreme poverty because of the cost of healthcare (source).
Contributing to sustainable development is at the heart of Bayer's corporate strategy. Through our work we aim to achieve long-term returns for the business while generating a positive impact for society and the environment. We have set ambitious 2030 targets to help people thrive as well as decrease our ecological footprint, in line with the Sustainable Development Goals of the United Nations and the Paris Agreement.
Fostering equitable healthcare for a growing world
At Bayer, we envision a world where all people can share in medical progress and live healthier and better lives, regardless of their income or background. The ambitious vision of healthcare for all and gender equality is enshrined in the UN Sustainable Development Goals (SDG 3 and 5) and is shared by many around the world.
Now more than ever, progress cannot be achieved without partnerships. As such, we are actively collaborating with NGOs, governments, and other public and private organizations, such as the Bill and Melinda Gates Foundation, Access Accelerated and the Antimicrobial Resistance Action Fund, to extend our reach and impact. Going forward, we will look to broaden and deepen partnerships with like-minded organizations in pursuit of our vision.
Setting clear goals to expand access to healthcare for all
As a leading pharmaceutical company, we see it as our responsibility to help expand access to healthcare for all. For this reason, we focus our effort in areas where we can have the most impact by leveraging our scientific expertise, products, partnerships and global network. Learn more from Bayer’s Access Charter, which you can find here.
Where We Focus Our Efforts
Using our heritage in women’s health to drive equality and prosperity
Just as access to healthcare is at the foundation of prosperous societies, access to family planning empowers women and promotes gender equality, which, in turn, results in increased economic and social development, and healthier societies overall. According to the UN, however, over 200 million women of reproductive age in low and middle-income countries (LMICs) who want to avoid pregnancy don't use safe and effective family planning methods (source).
We believe that all women should have access to voluntary family planning no matter their economic status, helping improve their health, economic opportunities and progress towards gender equality.
Driving success through our impact-generation business model
At Bayer, we believe sustainability should be at the core of every decision we make – from how we innovate and produce our products to how we enable equitable access to healthcare and contraception. This is why we have set ourselves the goal to become an impact generator, which means integrating sustainability into our business strategy. We have committed to pursuing our sustainability targets with the same rigor that we do our financial ones. Put simply, if we are successful in achieving our commitments, we will be generating inclusive growth from which everyone will benefit.
As our commitments are an essential element in our business, we will be quantifiably measuring and regularly reporting on our progress. We’ll be working with independent third-party organizations to audit our progress against our targets, which incidentally are also a component of our executives’ compensation. Furthermore, we established an independent Sustainability Council, that will advise our CEO and Board of Management on all matters related to sustainability.
Learn more about our commitments and focus areas to drive towards Health for All.
On January 26th, 2021, the latest Access To Medicine Index Report was published by the Access to Medicine Foundation. The ATM Index analyses how 20 of the world's largest pharma companies are addressing access to medicine in over 100 low-and-middle-income countries for over 75 diseases, conditions and pathogens. It evaluates pharma companies in areas where they have the biggest potential and responsibility to make change, addressing three assessment areas namely ‘Governance of Access’, ‘Research and Development’ and ‘Product Delivery’.
We are pleased to say that in total, Bayer went up 3 places in this last ranking. We are now 13th out of 20 of the world’s largest pharmaceutical companies, as evaluated by the ATM Index.
Our strongest area is ‘Governance of Access’, where we landed in 8th place, largely driven by our corporate values, incentive systems and sustainability commitments. For ‘Product Delivery’, which has the highest weight within the index, we placed 11th. This was also instrumental in lifting our overall ranking. Our consistent engagement in Family Planning and Neglected Tropical Diseases builds a strong foundation in this area, as well as the broad geographical footprint in registrations of new products in high burden countries. And we will continue to work on ‘Research and Development’, where we scored lower, which is an area of the ATM Index that emphasizes the application of a structured access planning process within low-and-middle-income countries already during product development. We are confident that our new equitable pricing strategy and patient affordability programs will increasingly support access for patients in low-and middle-income countries for the next reporting period. In the meantime, we remain dedicated to ‘Health For All, Hunger For None’, always putting patients at the center of our initiatives, partnerships and innovations.